Simulation of phase III studies of motesanib 125 mg once daily (QD) plus carboplatin/paclitaxel (CPM) or bevacizumab plus carboplatin/paclitaxel (CPB) versus carboplatin/paclitaxel (CP) in first-line non-small cell lung cancer (NSCLC) using a public domain drug–disease modeling framework and phase II data.
2010 ◽
Vol 28
(15_suppl)
◽
pp. e18089-e18089
Keyword(s):
2004 ◽
Vol 59
(4)
◽
pp. 943-951
◽
Keyword(s):
2007 ◽
Vol 2
(8)
◽
pp. S693-S694
Keyword(s):
Keyword(s):
2020 ◽
Vol 38
(31)
◽
pp. 3592-3603
◽
Keyword(s):
Keyword(s):
2014 ◽
Vol 32
(19)
◽
pp. 2059-2066
◽
Keyword(s):
2008 ◽
Vol 26
(15_suppl)
◽
pp. 8016-8016
◽
Keyword(s):
2011 ◽
Vol 29
(15_suppl)
◽
pp. e18004-e18004
◽
Keyword(s):
2011 ◽
Vol 29
(15_suppl)
◽
pp. 7551-7551
◽
Keyword(s):